Skip to main content
. 2017 Aug 8;318(6):557–566. doi: 10.1001/jama.2017.9938

Figure 4. Overall Survival and Hematological Relapse.

Figure 4.

In this modified intention-to-treat analysis set, data cutoff was April 26, 2017. Crosses on the curves indicate censored observations.

A, The median (interquartile range [IQR]) follow-up for overall survival in the azithromycin group was 18.6 months (IQR, 7.2-23.5) and was 20.6 months (IQR, 9.0-24.1) for placebo group.

B, The median (IQR) follow-up for hematologic relapse was 15.5 months (IQR, 4.4-23.1) for the azithromycin group and was 18.8 months (IQR, 6.0-23.8) for the placebo group.